Balyasny Asset Management LLC Nuvation Bio Inc. Transaction History
Balyasny Asset Management LLC
- $61.9 Billion
- Q2 2025
A detailed history of Balyasny Asset Management LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 132,296 shares of NUVB stock, worth $681,324. This represents 0.0% of its overall portfolio holdings.
Number of Shares
132,296Holding current value
$681,324% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding NUVB
# of Institutions
195Shares Held
168MCall Options Held
2.31MPut Options Held
221K-
Decheng Capital LLC Menlo Park, CA26MShares$134 Million12.78% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$83.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.9MShares$81.9 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA11MShares$56.9 Million46.36% of portfolio
-
Laurion Capital Management LP New York, NY10.2MShares$52.7 Million0.37% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $1.12B
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...